243 related articles for article (PubMed ID: 31646714)
1. Early administration of pegfilgrastim for esophageal cancer treated with docetaxel, cisplatin, and fluorouracil: A phase II study.
Ishikawa T; Yasuda T; Okayama T; Dohi O; Yoshida N; Kamada K; Uchiyama K; Takagi T; Konishi H; Shiozaki A; Fujiwara H; Konishi H; Naito Y; Teramukai S; Itoh Y
Cancer Sci; 2019 Dec; 110(12):3754-3760. PubMed ID: 31646714
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for febrile neutropenia and effectiveness of primary prophylaxis with pegfilgrastim in patients with esophageal cancer treated with docetaxel, cisplatin, and 5-fluorouracil.
Ohkura Y; Ueno M; Udagawa H
World J Surg Oncol; 2019 Jul; 17(1):125. PubMed ID: 31315622
[TBL] [Abstract][Full Text] [Related]
3. Pegfilgrastim for the management of neutropenia during neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in esophageal cancer patients.
Yoshimoto T; Oshima T; Fukada T; Imamura N; Nakanishi T; Ebisutani N; Morishita D; Mieno M; Nakai K; Sei H; Kitayama Y; Eda H; Okugawa T; Tomita T; Fukui H; Shinzaki S
Int J Clin Oncol; 2024 Feb; 29(2):142-148. PubMed ID: 38063978
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel, cisplatin, and fluorouracil with pegfilgrastim on day 3 as neoadjuvant chemotherapy for esophageal cancer.
Maeda O; Furune S; Kanda M; Miyata K; Shimizu D; Sugita S; Nishida K; Ando M; Kodera Y; Ando Y
Cancer Med; 2024 Jan; 13(2):e6974. PubMed ID: 38348961
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of pegfilgrastim administration in patients with esophageal cancer treated with docetaxel, cisplatin, and 5-fluorouracil.
Yoshida Y; Komori K; Aoki M; Sandou M; Takagi M; Uejima E
Pharmazie; 2018 Oct; 73(10):613-616. PubMed ID: 30223928
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Cost-effectiveness of Pegfilgrastim for Preventing Febrile Neutropenia During Docetaxel, Cisplatin, and 5-Fluorouracil Therapy for Esophageal Cancer.
Kurogochi T; Matsumoto A; Nyumura Y; Tanishima Y; Nakayoshi T; Okamoto T; Yano F; Eto K
Anticancer Res; 2023 May; 43(5):2293-2298. PubMed ID: 37097646
[TBL] [Abstract][Full Text] [Related]
7. [Impact of Primary Prophylaxis with Pegfilgrastim on Clinical Outcomes in Patients with Advanced Esophageal Cancer Receiving Chemotherapy with Docetaxel, Cisplatin ,and 5-FU].
Yasuda T; Ishikawa T; Ohta T; Yoshida J; Doi T; Dohi O; Okayama T; Yoshida N; Kamada K; Uchiyama K; Handa O; Takagi T; Konishi H; Shiozaki A; Fujiwara H; Naito Y; Itoh Y
Gan To Kagaku Ryoho; 2018 Dec; 45(12):1733-1736. PubMed ID: 30587730
[TBL] [Abstract][Full Text] [Related]
8. Preoperative docetaxel, cisplatin, and fluorouracil treatment with pegfilgrastim on day 7 for patients with esophageal cancer: A phase II study.
Maeda O; Fukaya M; Koike M; Miyata K; Kanda M; Nishida K; Ando M; Kodera Y; Ando Y
Asia Pac J Clin Oncol; 2022 Dec; 18(6):578-585. PubMed ID: 35043574
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of primary prophylaxis of febrile neutropenia with pegfilgrastim in docetaxel, cisplatin and 5-fluorouracil therapy for esophageal cancer.
Ichimura T; Nomura H; Shimizu H; Machida Y; Suzuki K
Pharmazie; 2021 Sep; 76(9):450-454. PubMed ID: 34481537
[No Abstract] [Full Text] [Related]
10. Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.
Kim S; François E; André T; Samalin E; Jary M; El Hajbi F; Baba-Hamed N; Pernot S; Kaminsky MC; Bouché O; Desrame J; Zoubir M; Ghiringhelli F; Parzy A; De La Fouchardiere C; Smith D; Deberne M; Spehner L; Badet N; Adotevi O; Anota A; Meurisse A; Vernerey D; Taieb J; Vendrely V; Buecher B; Borg C
Lancet Oncol; 2018 Aug; 19(8):1094-1106. PubMed ID: 30042063
[TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of Pegfilgrastim When Given Less Than 14 Days Before the Next Chemotherapy Cycle: Review of Every 14-Day Chemotherapy Regimen Containing 5-FU Continuous Infusion.
Donkor KN; Selim JH; Waworuntu A; Lewis K
Ann Pharmacother; 2017 Oct; 51(10):840-847. PubMed ID: 28597691
[TBL] [Abstract][Full Text] [Related]
12. [Successful Treatment of Advanced Esophageal Cancer with DCF Chemotherapy and Pegfilgrastim].
Gunjigake K; Okamoto K; Gabata R; Yamaguchi T; Ninomiya I; Fushida S; Ohta T
Gan To Kagaku Ryoho; 2019 Jan; 46(1):61-63. PubMed ID: 30765644
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of Prophylactic Administration of Pegfilgrastim for Esophageal Cancer Chemotherapy: A Single-center Retrospective Study.
Okamoto K; Ninomiya I; Saito H; Shimada M; Yamaguchi T; Terai S; Moriyama H; Kinoshita J; Nakamura K; Inaki N
Anticancer Res; 2022 May; 42(5):2783-2790. PubMed ID: 35489772
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for febrile neutropenia in neoadjuvant docetaxel, cisplatin, and 5-fluorouracil chemotherapy for esophageal cancer.
Nomura H; Hatogai K; Maki Y; Mochizuki N; Tanaka M; Saito S; Daiko H; Kojima T; Kawasaki T
Support Care Cancer; 2020 Apr; 28(4):1849-1854. PubMed ID: 31342165
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant Chemotherapy with Divided-dose Docetaxel, Cisplatin and Fluorouracil for Patients with Squamous Cell Carcinoma of the Esophagus.
Ojima T; Nakamori M; Nakamura M; Katsuda M; Hayata K; Kato T; Kitadani J; Tabata H; Takeuchi A; Iwahashi M; Yamaue H
Anticancer Res; 2016 Feb; 36(2):829-34. PubMed ID: 26851048
[TBL] [Abstract][Full Text] [Related]
16. Prophylactic pegfilgrastim to prevent febrile neutropenia among patients receiving biweekly (Q2W) chemotherapy regimens: a systematic review of efficacy, effectiveness and safety.
Mahtani R; Crawford J; Flannery SM; Lawrence T; Schenfeld J; Gawade PL
BMC Cancer; 2021 May; 21(1):621. PubMed ID: 34044798
[TBL] [Abstract][Full Text] [Related]
17. A single-arm, retrospective analysis of the incidence of febrile neutropenia using same-day versus next-day pegfilgrastim in patients with gastrointestinal cancers treated with FOLFOX or FOLFIRI.
Eckstrom J; Bartels T; Abraham I; Patel H; Elquza E; Scott AJ; Malangone S; Hollings J; McBride A
Support Care Cancer; 2019 Mar; 27(3):873-878. PubMed ID: 30090991
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II study of divided-dose docetaxel, cisplatin and fluorouracil for patients with recurrent or metastatic squamous cell carcinoma of the esophagus.
Ojima T; Nakamori M; Nakamura M; Katsuda M; Hayata K; Matsumura S; Iwahashi M; Yamaue H
Dis Esophagus; 2017 Feb; 30(2):1-7. PubMed ID: 26725778
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of first-line systemic chemotherapy with epirubicin, cisplatin plus 5-fluorouracil and docetaxel, cisplatin plus 5-fluorouracil regimens in locally advanced inoperable or metastatic gastric or gastroesophageal junction adenocarcinoma: A prospective phase II study from South India.
Babu KG; Chaudhuri T; Lakshmaiah KC; Dasappa L; Jacob LA; Babu M; Rudresha AH; Lokesh KN; Rajeev LK
Indian J Cancer; 2017; 54(1):47-51. PubMed ID: 29199662
[TBL] [Abstract][Full Text] [Related]
20. Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501-P2).
Higuchi K; Komori S; Tanabe S; Katada C; Azuma M; Ishiyama H; Sasaki T; Ishido K; Katada N; Hayakawa K; Koizumi W;
Int J Radiat Oncol Biol Phys; 2014 Jul; 89(4):872-9. PubMed ID: 24867539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
